Invesco Ltd. Purchases 365,468 Shares of Roivant Sciences Ltd. $ROIV

Key Points

• Invesco Ltd. increased its stake in Roivant Sciences Ltd. by 3.8%, owning 9,880,526 shares valued at approximately $99.7 million as of its latest SEC filing.
• Other hedge funds have also raised their positions, with TOMS Capital increasing holdings by 46.6% and Marshall Wace by 104.4% during the fourth quarter.
• Roivant Sciences had a negative net margin of 2,111.79% and reported earnings per share of ($0.31), missing analysts' estimates by ($0.15).

Invesco Ltd. boosted its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 3.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,880,526 shares of the company's stock after acquiring an additional 365,468 shares during the period. Invesco Ltd. owned 1.38% of Roivant Sciences worth $99,695,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. Covestor Ltd grew its stake in Roivant Sciences by 65.6% during the first quarter. Covestor Ltd now owns 34,175 shares of the company's stock valued at $345,000 after acquiring an additional 13,541 shares in the last quarter. Citigroup Inc. grew its stake in Roivant Sciences by 12.8% in the 1st quarter. Citigroup Inc. now owns 720,387 shares of the company's stock worth $7,269,000 after buying an additional 81,482 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in Roivant Sciences by 9.1% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 17,110 shares of the company's stock worth $173,000 after buying an additional 1,434 shares in the last quarter. CenterBook Partners LP purchased a new position in Roivant Sciences in the 1st quarter worth approximately $1,531,000. Finally, Charles Schwab Investment Management Inc. grew its stake in Roivant Sciences by 1.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,847,625 shares of the company's stock worth $28,733,000 after buying an additional 35,123 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company's stock.

Insiders Place Their Bets

In other news, CEO Eric Venker sold 100,000 shares of the company's stock in a transaction on Monday, July 21st. The shares were sold at an average price of $11.52, for a total value of $1,152,000.00. Following the completion of the sale, the chief executive officer owned 1,462,223 shares of the company's stock, valued at approximately $16,844,808.96. This represents a 6.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Vivek Ramaswamy sold 577,007 shares of the company's stock in a transaction on Friday, June 20th. The shares were sold at an average price of $11.46, for a total transaction of $6,612,500.22. Following the completion of the sale, the insider directly owned 37,284,108 shares of the company's stock, valued at $427,275,877.68. This trade represents a 1.52% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 3,090,503 shares of company stock valued at $34,991,546 in the last ninety days. 10.80% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. The Goldman Sachs Group raised shares of Roivant Sciences to a "strong-buy" rating and set a $19.00 price target for the company in a research note on Thursday, July 10th. HC Wainwright reissued a "buy" rating and issued a $18.00 price target on shares of Roivant Sciences in a research note on Wednesday, June 18th. Two analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $16.50.

Roivant Sciences Stock Up 0.8%

Shares of Roivant Sciences stock traded up $0.09 during trading on Thursday, reaching $11.81. The company's stock had a trading volume of 3,280,852 shares, compared to its average volume of 4,510,177. Roivant Sciences Ltd. has a 52-week low of $8.73 and a 52-week high of $13.06. The company has a market cap of $8.03 billion, a price-to-earnings ratio of -16.87 and a beta of 1.15. The firm's 50-day moving average is $11.42 and its two-hundred day moving average is $10.91.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its quarterly earnings data on Thursday, May 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.15). Roivant Sciences had a negative net margin of 2,111.79% and a negative return on equity of 15.90%. The business had revenue of $7.57 million during the quarter, compared to analysts' expectations of $62.17 million. During the same period last year, the company posted ($0.23) EPS. On average, equities research analysts anticipate that Roivant Sciences Ltd. will post -0.92 EPS for the current year.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.